MicroRNAs for osteosarcoma in the mouse: a meta-analysis

Junli Chang, Min Yao, Yimian Li, Dongfeng Zhao, Shaopu Hu, Xuejun Cui, Gang Liu, Qi Shi, Yongjun Wang and Yanping Yang _

PDF  |  HTML  |  How to cite  |  Order a Reprint

Oncotarget. 2016; 7:85650-85674. https://doi.org/10.18632/oncotarget.13333

Metrics: PDF 2349 views  |   HTML 1972 views  |   ?  


Junli Chang1,2, Min Yao1,2, Yimian Li1,2, Dongfeng Zhao1,2, Shaopu Hu1,2, Xuejun Cui1,2, Gang Liu3, Qi Shi1,2, Yongjun Wang1,2,4 and Yanping Yang1,2

1 Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China

2 Spine Institute, Shanghai University of Traditional Chinese Medicine, Shanghai, China

3 Division of Pulmonary and Critical Care Medicine, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA

4 School of Rehabilitation Science, Shanghai University of Traditional Chinese Medicine, Shanghai, China

Correspondence to:

YanpingYang, email:

Keywords: miRNA; osteosarcoma; meta-analysis; mouse; therapeutic target

Received: January 25, 2016 Accepted: September 25, 2016 Published: November 12, 2016


Osteosarcoma (OS) is the most common primary malignant bone carcinoma with high morbidity that happens mainly in children and young adults. As the key components of gene-regulatory networks, microRNAs (miRNAs) control many critical pathophysiological processes, including initiation and progression of cancers. The objective of this study is to summarize and evaluate the potential of miRNAs as targets for prevention and treatment of OS in mouse models, and to explore the methodological quality of current studies. We searched PubMed, Web of Science, Embase, Wan Fang Database, VIP Database, China Knowledge Resource Integrated Database, and Chinese BioMedical since their beginning date to 10 May 2016. Two reviewers separately screened the controlled studies, which estimate the effects of miRNAs on osteosarcoma in mice. A pair-wise analysis was performed. Thirty six studies with enough randomization were selected and included in the meta-analysis. We found that blocking oncogenic or restoring decreased miRNAs in cancer cells could significantly suppress the progression of OS in vivo, as assessed by tumor volume and tumor weight. This meta-analysis suggests that miRNAs are potential therapeutic targets for OS and correction of the altered expression of miRNAs significantly suppresses the progression of OS in mouse models, however, the overall methodological quality of studies included here was low, and more animal studies with the rigourous design must be carried out before a miRNA-based treatment could be translated from animal studies to clinical trials.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 13333